AMGN (NASDAQ) - Amgen Inc
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Common Stock • ISIN: US0311621009
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Web URL:
Market Cap. | 116,521m USD |
GiC Sector | Health Care |
GiC Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1983-06-17 |
Ratings
Fundamental | 2.36 |
Dividend | 8.05 |
Performance 5y | 3.87 |
Performance TTM | -0.22 |
Relative Performance | -4.10 |
Analysts | 3.42 |
Price / Fair Price TR | 1.10 |
Price / Fair Price DCF | todo |
Technical
Growth TTM | -7.08% |
CAGR 5y | 6.83% |
CAGR / Mean Drawdown 5y | 0.87 |
Sharpe Ratio TTM | -0.57 |
Alpha vs SP500 TTM | -10.30 |
Beta vs SP500 5y weekly | 0.53 |
CAPM | 7.52% |
Average Daily Range % | 1.73% |
Volatility GJR Garch 1y | 22.95% |
Max Drawdown 5y | 25% |
Mean Drawdown 5y | 7.9% |
Price / SMA 50 | -5.42% |
Price / SMA 200 | -9.75% |
Current Volume | 1814.5k |
Average Volume | 2348.7k |
Dividends
Rate TTM | 8.14 |
Yield TTM | 3.68% |
Div. CAGR 5y | 8.01% |
Consistency of Dividends all time | 100.0% |